Premium
Citalopram
Author(s) -
Joubert Andre F.,
Sánchez Connie,
Larsen Frank
Publication year - 2000
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/1099-1077(200008)15:6<439::aid-hup222>3.0.co;2-h
Subject(s) - citalopram , antidepressant , serotonin reuptake inhibitor , reuptake inhibitor , drug , serotonin uptake inhibitors , medicine , pharmacology , serotonin transporter , serotonin , psychiatry , psychology , fluoxetine , anxiety , receptor
Citalopram is a selective serotonin (5‐HT) reuptake inhibitor (SSRI) developed by H. Lundbeck A/S in Denmark. It is the most selective serotonin antidepressant with proven efficacy, a favourable pharmacokinetic profile and a low potential for interactions with other concomitant medication. The drug has a low incidence of side effects, even when compared to the other SSRIs and good patient compliance and satisfaction is a feature of this drug. These factors make the drug a good choice for depressed patients who require continuation and long‐term treatment, as well as for elderly patients. Copyright © 2000 John Wiley & Sons, Ltd.